RARECast

RARECast

By RARECastBusiness
Download on the App Store

RARECast episodes

  • A Teenager's Transformation from Patient to Advocate
    As a child, Sami Petersen developed progressive scoliosis, a severe curvature of the spine as a result of a rare genetic disease. The condition eventually led to complex spinal surgery to correct the worsening deformity, pain, and complications. As she recovered from her operation, Petersen, who was 15 at the time, decided to launch the organization SHIFT Scoliosis, which has grown from a small awareness initiative to an organization that is reaching thousands of people through its education, awareness, and outreach programs. As part of a series of podcast revisiting past winners of Global Genes Champions of Hope award, we spoke to Petersen, a 2014 teen advocacy honoree, about her experience with scoliosis, what led her to launch SHIFT, and how she’s reaching people around the world.
    18 min
  • How the Orphan Drug Act Reshaped the Rare Disease Landscape
    The U.S. Food and Drug Administration approved more than 230 new drugs to treat rare diseases in the past decade and there are currently more than 450 orphan drugs in development, according to a new report (http://onphr.ma/1EsGJw6) from the Pharmaceutical Research and Manufacturers of America. Though developing drugs for rare diseases presents many challenges, policy changes and scientific breakthroughs have helped changed the landscape. We spoke to Gretta Stone, Deputy Vice President of Policy and Research at PhRMA, about the report, how the Orphan Drug Act encouraged investment in R&D for rare diseases, and what fuels her optimism for drug development efforts to combat this group of diseases in the years ahead. Also, we check in with Run4Rare's Noah Coughlan as he continues his 3,100 mile run across the country to raise awareness for rare diseases.
    29 min
  • Why the OPEN ACT Could Greatly Expand Treatments for Rare Disease
    Though there are almost 7,000 rare diseases, less than 500 drugs have been approved to treat any one of them. What that means for millions of people with a rare disease is that there’s no approved treatment they can use. There is, however, a growing effort to look at drugs approved for other uses and repurpose them to treat rare diseases in which they might be effective. We spoke to Julia Jenkins, executive director of the EveryLife Foundation for Rare Diseases about why repurposing approved drugs could greatly increase the available treatments for rare diseases, what draft legislation would do to encourage drugmakers to pursue these opportunities, and why experiences from past legislation suggest the approach could be quite effective.
    16 min
  • Rare Disease Company Seeks 100 Drugs in 10 Years
    Recursion Pharmaceuticals has set the audacious goal for itself of developing 100 drugs in 10 years for rare diseases. The company, focused on repurposing compounds abandoned in clinical development by other drugmakers, thinks it can achieve this by a fundamentally different approach to drug development than the industry’s traditional process of screening compounds against potential disease targets. We spoke to Chris Gibson, founder and CEO of Recursion, about the approach his company is taking, whether rare diseases particularly lend themselves to it, and whether it has implications more broadly for drug development.
    22 min
  • A Run Across America to Raise Rare Disease Awareness
    Noah Coughlan will set out on a 3,100 mile run across America from the Statue of Liberty to San Diego’s Ocean Beach in the hope of raising awareness and support in the fight against rare diseases. It will be the third run across the country for the founder of the Run4Rare Foundation and begin on February 28, World Rare Disease Day. We spoke to Coughlan about his run, what motivated him to do this, and what he hopes to accomplish.
    20 min
  • Tapping the Public to Keep Scientists Current on Rare Disease Research
    The search for cures for diseases is limited by the ability of scientists to consume and understand the rapidly expanding volumes of biomedical literature produced each year. Andrew Su, associate professor in the department of Molecular and Experimental Medicine at The Scripps Research Institute, has a solution. He wants to enlist members of the rare disease community and general public to become citizen scientists and pour through biomedical journals to help find connections and identify research in one area that may shed light on another. We spoke to Su about his project Mark2Cure, the role crowdsourcing can play in accelerating rare disease research, and why members of the rare disease community may better suited for elucidating important findings than supercomputers.
    22 min
  • Why Raising Awareness Matters in the Fight Against Rare Diseases
    World Rare Disease Day, an annual observance held on the last day of February, seeks to raise awareness for rare diseases. On that day, hundreds of patient organizations from more than 80 countries will be participating in activities to call attention to thousands of ailments, many of which are without treatments or even names. We spoke to Hudson Freeze, director of the Human Genetics Program at Sanford Burham Medical Research Institute, about World Rare Disease Day, the importance of raising awareness, and how research into rare diseases can shed light into more common ailments.
    25 min
  • The First Lady's Date who Embodied Precision Medicine
    At the age of 8, Bill Elder, Jr. was diagnosed with cystic fibrosis, a rare, genetic disease expected to cut his life short. Now a third year medical student, Elder has been the beneficiary of Vertex Pharmaceutical’s Kalydeco, an example of the transformative effects personalized therapies can have on patients. As President Barack Obama announced plans for a precision medicine initiative during his State of the Union address, Elder sat alongside First Lady Michelle Obama as a living and breathing testament to the promise of precision medicine. We spoke to Elder about his recent visit to Washington, his experience with cystic fibrosis, and the difference Kalydeco has made in his life.
    15 min
  • Startup with NIH Deal Seeks to Speed Drugs for Rare Diseases
    The combination of high cost, long development times, and small patient populations for rare diseases is driving new models to accelerate drug development. The story of the newly formed rare disease company Vtesse is a compelling example. Driven by parents, advanced to the clinic by the National Institutes of Health, and licensed by a new company formed out of an orphan drug accelerator, Vtesse is advancing an experimental drug to treat Niemann Pick Disease Type C and other lysosomal storage disorders. We spoke to Ben Machielse, CEO of Vtesse, about his company, the unusual collaborations that led to its formation, and what it says about how patients, government, investors, and industry can work together to speed the development of new therapies for rare diseases.
    18 min
  • Expanding the Potential of Crowdfunding
    Crowdfunding, once thought of as little more than a way to raise money for small scientific projects, is increasingly being used to raise significant capital to fund startups. Perlstein Lab, a San Francisco-based starup focused on finding new drugs to treat rare diseases, raised more than $2 million using crowdfunding. We spoke to Ethan Perlstein, founder and CEO of Perlstein Lab, about his company, the potential of crowdfunding, and the unusual role social media has played in his efforts to raise capital.
    16 min

About RARECast

From the publisher's feed

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.